肝硬化和肝炎中的前激肽释放酶和激肽释放酶抑制剂

Prekallikein and kallikrein inhibitor in liver cirrhosis and hepatitis.

作者信息

Faciullacci M, Galli P, Monetti M G, Pela I, Del Bianco P L

出版信息

Adv Exp Med Biol. 1976;70(00):201-8. doi: 10.1007/978-1-4684-3267-1_25.

Abstract

Plasma prekallikrein (kallikreinogen) and kallikrein inhibitor, assayed with the kaolin activable esterase method, have been evaluated in 20 patients with hepatic cirrhosis, in 12 cases with jaundice from acute viral hepatitis, and in 9 normal. A significant reduction of the plasma prekallikrein in cirrhosis has been found. A lowering of plasma prekallikrein has also been observed in viral hepatitis; in this condition, however, the modifications were less important than those obtained in cirrhosis. In three cases of hepatitis, the behaviour of the plasma prekallikrein and kallikrein inhibitor have been controlled during the period of the disease and compared with the behaviour of some conventional parameters, such as serum transaminases and bilirubin. An important increase of the prekallikrein level has been observed during the improvement of hepatitis. These data confirm the implication of the prekallikrein-kallikrein system in severe liver diseases, and indirectly points out the role of the liver in maintaining the physiological balance of the kallikrein system.

摘要

采用高岭土激活酯酶法检测了20例肝硬化患者、12例急性病毒性肝炎黄疸患者和9名正常人的血浆前激肽释放酶（激肽原）及激肽释放酶抑制剂。发现肝硬化患者血浆前激肽释放酶显著降低。病毒性肝炎患者也观察到血浆前激肽释放酶降低；然而，在这种情况下，其变化不如肝硬化患者明显。在3例肝炎患者中，在病程中监测了血浆前激肽释放酶和激肽释放酶抑制剂的变化，并与一些传统参数如血清转氨酶和胆红素的变化进行了比较。肝炎好转期间观察到前激肽释放酶水平显著升高。这些数据证实了前激肽释放酶-激肽释放酶系统在严重肝脏疾病中的作用，并间接指出了肝脏在维持激肽释放酶系统生理平衡中的作用。